Correlation of MRI Biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats

Neoplasia

Volumn 9, Issue 5, 2007, Pages 382-391

  Bradley, Daniel P ^a   Tessier, Jean J ^a   Ashton, Susan E ^a   Waterton, John C ^a   Wilson, Zena ^a   Worthington, Philip L ^a   Ryan, Anderson J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Magnetic resonance imaging; Necrosis; Vascular damaging agent; Xenograft; ZD6126

Indexed keywords

BIOLOGICAL MARKER; GADOLINIUM; GADOLINIUM PENTETATE; N ACETYLCOLCHINOL PHOSPHATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MARKER; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; PRIORITY JOURNAL; RAT; SIGNAL DETECTION; SUBCUTANEOUS TISSUE TUMOR; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 34249006207     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07145     Document Type: Article

References (48)

1. Folkman J (1985). Tumor angiogenesis. Adv Cancer Res 43, 175-203.
2. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
3. Fox SB, Gasparini G, and Harris AL (2001). Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2, 278-289.
4. Thorpe PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
5. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, et al. (2002). ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62, 7247-7253.
6. Gotlieb AI (1990). The endothelial cytoskeleton: organization in normal and regenerating endothelium. Toxicol Pathol 18, 603-617.
7. McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, and Waterton JC (2004). Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia 6, 150-157.
8. Blakey DC, Ashton SE, Westwood FR, Walker M, and Ryan AJ (2002). ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1497-1502.
9. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, and Ryan AJ (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8, 1974-1983.
10. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, and Tozer GM (2001). Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21, 93-102.
11. Kanthou C and Tozer GM (2002). The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060-2069.
12. Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MM, Semmler W, et al. (2004). Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 6, 213-223.
13. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, and LoRusso PM (2005). Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11, 416-420.
14. Beauregard DA, Hill SA, Chaplin DJ, and Brindle KM (2001). The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61, 6811-6815.
15. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, et al. (2004). Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10, 3650-3657.
16. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, and Rustin GJ (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21, 2831-2842.
17. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
18. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, et al. (2004). Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non - small cell lung cancer xenograft model. Mol Cancer Ther 3, 977-983.
19. Siemann DW and Rojiani AM (2002). Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53, 164-171.
20. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, et al. (2005). The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92, 1599-1610.
21. Tofts PS and Kermode AG (1991). Measurement of the blood - brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 17, 357-367.
22. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al. (1999). Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10, 223-232.
23. drup-Link HE, Simon GH, and Brasch RC (2006). Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des 12, 2661-2672.
24. Jeswani T and Padhani AR (2005). Imaging tumour angiogenesis. Cancer Imaging 5, 131-138.
25. Kiessling F, Morgenstern B, and Zhang C (2007). Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem 14, 77-91.
26. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, and Tozer GM (2002). Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15, 89-98.
27. Neeman M, Dafni H, Bukhari O, Braun RD, and Dewhirst MW (2001). In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med 45, 887-898.
28. Kiselev VG, Strecker R, Ziyeh S, Speck O, and Hennig J (2005). Vessel size imaging in humans. Magn Reson Med 53, 553-563.
29. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, and Decorps M (2001). Vessel size imaging. Magn Reson Med 45, 397-408.
30. Tropres I, Lamalle L, Farion R, Segebarth C, and Remy C (2004). Vessel size imaging using low intravascular contrast agent concentrations. MAGMA 17, 313-316.
31. Baudelet C, Cron GO, and Gallez B (2006). Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors. Magn Reson Med 56, 1041-1049.
32. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, and Padhani AR (2002). Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20, 3826-3840.
33. Lagarias JC, Reeds JA, Wright MH, and Wright PE (1998). Convergence properties of the Nelder-Mead Simplex Method in low dimensions. SIAM J Optim 9, 112-147.
34. 99mTc(DTPA) in rats. Magn Reson Imaging 8, 567-575.
35. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, and Brindle KM (1998). Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77, 1761-1767.
36. Beauregard DA, Pedley RB, Hill SA, and Brindle KM (2002). Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15, 99-105.
37. Prise VE, Honess DJ, Stratford MR, Wilson J, and Tozer GM (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21, 717-726.
38. Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, Chaplin DJ, and Edvardsen K (2004). Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 111, 604-610.
39. Gadgeel S, LoRusso PM, Wozniak A, and Wheeler C (2002). A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumours. Proc Am Soc Clin Oncol 21, 438.
40. 14C]-ZD6126 in patients with solid malignant tumours. Proc Am Soc Clin Oncol 145, 3083.
41. 14C-ZD6126) to tumour-bearing mice. Xenobiotica 37, 328-340.
42. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, and Hermans R (2005). Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234, 756-764.
43. Cline JM, Thrall DE, Page RL, Franko AJ, and Raleigh JA (1990). Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours. Br J Cancer 62, 925-931.
44. Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, and Waterton JC (2005). Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7, 466-474.
45. Morgan B, Higginson T, and Horsfield MA (2005). Reproducibility of a single slice, single region method for monitoring the effect of treatment of metastases using dynamic contrast enhanced MRI. Proc Int Soc Magn Reson Med, 412.
46. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, et al. (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21, 3955-3964.
47. Henning EC, Azuma C, Sotak CH, and Helmer KG (2007). Multispectral quantification of tissue types in a RIF-1 tumor model with histological validation: Part I. Magn Reson Med 57, 501-512.
48. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, et al. (2005). Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin A-4 phosphate after repeated administration. Neoplasia 7, 779-787.